David O’Malley, MD, Discusses Findings From the OReO Trial in Ovarian Cancer at 2021 ESMO
September 23rd 2021CancerNetwork® sat down with David O’Malley, MD, at the 2021 European Society for Medical Oncology to talk about the OReO trial and how these findings impact what’s already known about PARP inhibitors for the treatment of ovarian cancer.
Jason Luke, MD, Discusses Advancement of Immunotherapy For Metastatic Disease at 2021 ESMO
September 22nd 2021CancerNetwork® sat down with Jason Luke, MD, at the 2021 European Society for Medical Oncology Congress to talk about the latest developments in the use of immunotherapy for metastatic disease.
Metastases and Variant Histology in Urothelial Cancer
September 14th 2021Thomas Powles, MBBS, MRCP, MD, leads the discussion on selecting chemotherapy vs immune checkpoint inhibitors in the adjuvant setting for a patient who has metastases in urothelial carcinoma as well as approaching therapy for variant histology.
Larry Anderson, MD, PhD, Discusses CAR T-Cell Therapy For Multiple Myeloma at 2021 IMW
September 10th 2021CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 18th International Myeloma Workshop to talk about how the emergence of CAR T-cell therapies in multiple myeloma affects multidisciplinary clinicians.